Cargando…

Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population

Background: Rituximab is used as second-line therapy in patients with immune thrombocytopenic purpura (ITP) who do not respond to first-line management. The response rate for Rituximab is variable in different populations ranging from 30% to 90%. The adverse effects of rituximab in patients with ITP...

Descripción completa

Detalles Bibliográficos
Autores principales: Ata, Fateen, Yousaf, Zohaib, Zahir, Fathima Z., Mohamed Babiker, Anas, Ali Farooqi, Amer, Ahmad Al Hiyari, Mousa, Al Bozom, Adel Issam, Mohamed, Ahmed Hatim., Nashwan, Abdulqadir J., Yassin, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: HBKU Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272691/
https://www.ncbi.nlm.nih.gov/pubmed/35864918
http://dx.doi.org/10.5339/qmj.2022.22
_version_ 1784744924138176512
author Ata, Fateen
Yousaf, Zohaib
Zahir, Fathima Z.
Mohamed Babiker, Anas
Ali Farooqi, Amer
Ahmad Al Hiyari, Mousa
Al Bozom, Adel Issam
Mohamed, Ahmed Hatim.
Nashwan, Abdulqadir J.
Yassin, Mohamed A.
author_facet Ata, Fateen
Yousaf, Zohaib
Zahir, Fathima Z.
Mohamed Babiker, Anas
Ali Farooqi, Amer
Ahmad Al Hiyari, Mousa
Al Bozom, Adel Issam
Mohamed, Ahmed Hatim.
Nashwan, Abdulqadir J.
Yassin, Mohamed A.
author_sort Ata, Fateen
collection PubMed
description Background: Rituximab is used as second-line therapy in patients with immune thrombocytopenic purpura (ITP) who do not respond to first-line management. The response rate for Rituximab is variable in different populations ranging from 30% to 90%. The adverse effects of rituximab in patients with ITP range from infusion site reactions to the reactivation of hepatitis B virus and progressive multifocal leukoencephalopathy and interpopulation variation. Methods: We conducted a single-center, retrospective study in Qatar's National Center for Cancer Care & Research. The study included patients with chronic refractory ITP who received rituximab as second-line therapy. Descriptive and summary statistics were used to describe the sociodemographic parameters of the study cohort. Results: Of the 41 patients with chronic ITP, 26 were Arabs, 12 were Asians, and 3 were of other ethnicities. Rituximab was associated with an overall response rate of 80.4%. Arabic patients had the highest clinical response (84.6%) among the ethnicities with the lowest adverse effects (11.5%). Asians had a response rate of 66.6%, and adverse effects were seen in 16.7% of the patients. Conclusions: In chronic refractory ITP, rituximab appears to have a better clinical response in the Arabic population with minimal toxicity than in other ethnicities.
format Online
Article
Text
id pubmed-9272691
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher HBKU Press
record_format MEDLINE/PubMed
spelling pubmed-92726912022-07-20 Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population Ata, Fateen Yousaf, Zohaib Zahir, Fathima Z. Mohamed Babiker, Anas Ali Farooqi, Amer Ahmad Al Hiyari, Mousa Al Bozom, Adel Issam Mohamed, Ahmed Hatim. Nashwan, Abdulqadir J. Yassin, Mohamed A. Qatar Med J Research Paper Background: Rituximab is used as second-line therapy in patients with immune thrombocytopenic purpura (ITP) who do not respond to first-line management. The response rate for Rituximab is variable in different populations ranging from 30% to 90%. The adverse effects of rituximab in patients with ITP range from infusion site reactions to the reactivation of hepatitis B virus and progressive multifocal leukoencephalopathy and interpopulation variation. Methods: We conducted a single-center, retrospective study in Qatar's National Center for Cancer Care & Research. The study included patients with chronic refractory ITP who received rituximab as second-line therapy. Descriptive and summary statistics were used to describe the sociodemographic parameters of the study cohort. Results: Of the 41 patients with chronic ITP, 26 were Arabs, 12 were Asians, and 3 were of other ethnicities. Rituximab was associated with an overall response rate of 80.4%. Arabic patients had the highest clinical response (84.6%) among the ethnicities with the lowest adverse effects (11.5%). Asians had a response rate of 66.6%, and adverse effects were seen in 16.7% of the patients. Conclusions: In chronic refractory ITP, rituximab appears to have a better clinical response in the Arabic population with minimal toxicity than in other ethnicities. HBKU Press 2022-07-07 /pmc/articles/PMC9272691/ /pubmed/35864918 http://dx.doi.org/10.5339/qmj.2022.22 Text en © 2022 Ata, Yousaf, Zahir, Babiker, Ali Farooqi, Al Hiyari, Al Bozom, Mohamed, Nashwan, Yassin, licensee HBKU Press. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Ata, Fateen
Yousaf, Zohaib
Zahir, Fathima Z.
Mohamed Babiker, Anas
Ali Farooqi, Amer
Ahmad Al Hiyari, Mousa
Al Bozom, Adel Issam
Mohamed, Ahmed Hatim.
Nashwan, Abdulqadir J.
Yassin, Mohamed A.
Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population
title Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population
title_full Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population
title_fullStr Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population
title_full_unstemmed Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population
title_short Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population
title_sort efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: a descriptive study among the arabic population
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272691/
https://www.ncbi.nlm.nih.gov/pubmed/35864918
http://dx.doi.org/10.5339/qmj.2022.22
work_keys_str_mv AT atafateen efficacyandsafetyofrituximabassecondlinetherapyinimmunethrombocytopenicpurpurabasedonethnicityadescriptivestudyamongthearabicpopulation
AT yousafzohaib efficacyandsafetyofrituximabassecondlinetherapyinimmunethrombocytopenicpurpurabasedonethnicityadescriptivestudyamongthearabicpopulation
AT zahirfathimaz efficacyandsafetyofrituximabassecondlinetherapyinimmunethrombocytopenicpurpurabasedonethnicityadescriptivestudyamongthearabicpopulation
AT mohamedbabikeranas efficacyandsafetyofrituximabassecondlinetherapyinimmunethrombocytopenicpurpurabasedonethnicityadescriptivestudyamongthearabicpopulation
AT alifarooqiamer efficacyandsafetyofrituximabassecondlinetherapyinimmunethrombocytopenicpurpurabasedonethnicityadescriptivestudyamongthearabicpopulation
AT ahmadalhiyarimousa efficacyandsafetyofrituximabassecondlinetherapyinimmunethrombocytopenicpurpurabasedonethnicityadescriptivestudyamongthearabicpopulation
AT albozomadelissam efficacyandsafetyofrituximabassecondlinetherapyinimmunethrombocytopenicpurpurabasedonethnicityadescriptivestudyamongthearabicpopulation
AT mohamedahmedhatim efficacyandsafetyofrituximabassecondlinetherapyinimmunethrombocytopenicpurpurabasedonethnicityadescriptivestudyamongthearabicpopulation
AT nashwanabdulqadirj efficacyandsafetyofrituximabassecondlinetherapyinimmunethrombocytopenicpurpurabasedonethnicityadescriptivestudyamongthearabicpopulation
AT yassinmohameda efficacyandsafetyofrituximabassecondlinetherapyinimmunethrombocytopenicpurpurabasedonethnicityadescriptivestudyamongthearabicpopulation